Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...

The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.

On Monday, Nektar Therapeutics (NKTR) stock saw a modest uptick, ending the day at $1.33 which represents a slight increase of $0.10 or 8.13% from the prior close of $1.23. The stock opened at $1.37 ...

Nektar Therapeutics is selling off its only manufacturing facility as well as its reagent business to private equity firm Ampersand Capital Partners for $90 million. In the deal, which is ...

Fintel reports that on November 4, 2024, Piper Sandler initiated coverage of Nektar Therapeutics (NasdaqCM:NKTR) with a ...

California, USA-based biotech Nektar Therapeutics’ (Nasdaq: NKTR) shares closed up more than 8% at $1.33 yesterday after it ...

Therapeutics announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and ...

US stock markets finished lower on Monday as traders braced for volatility in the days ahead with the latest polls showing ...

Piper Sandler has initiated coverage on Nektar Therapeutics Inc (NASDAQ:NKTR), citing the company’s lead asset ...

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

(RTTNews) - Nektar Therapeutics (NKTR), Monday announced a decision to sell its Alabama-based commercial-scale manufacturing facility and PEGylation reagent supply business to Ampersand Capital ...